Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 791-802

  Cozzi Lepri, Alessandro ^a   Ruiz, Lidia ^b   Loveday, Clive ^c   Phillips, Andrew N ^a   Clotet, Bonaventura ^b   Reiss, Peter ^d   Ledergerber, Bruno ^e   Holkmann, Christian ^g   Staszewski, Schlomo ^f   Lundgren, Jens D ^g  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c International Clinical Virology Centre   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE; THYMIDINE; ZIDOVUDINE;

ARTICLE; CHRONOLOGY; CONFIDENCE INTERVAL; DATA ANALYSIS; DRUG ACTIVITY; FEMALE; GENOTYPE; HUMAN; LABORATORY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT; PLASMA; PRIORITY JOURNAL; STATISTICAL MODEL;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; RETROSPECTIVE STUDIES; THYMIDINE;

EID: 27844531602     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kuritzkes DR, Bassett RL, Hazelwood JD, Barrett H, Rhodes RA, Young RK, Johnson VA; Adult ACTG Protocol 306 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. The Journal of Infectious Diseases 2004; 36:600-603.
2. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A & Richman DD. Update of the Drug Resistance Mutations in HIV-1. Topics in HIV Medicine 2004; 12:119-124.
3. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS & Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. The Journal of Infectious Diseases 2003; 188:992-1000.
4. Fumero E & Podzamczer D. New patterns of HIV-1 resistance during HAART. Clinical Microbiology and Infection 2003; 9:1077-1084.
5. Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, Tisdale M & Lanier ER. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18:1691-1696.
6. Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattre P & Mouton Y. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. The Journal of Antimicrobial Chemotherapy 2004; 53:89-94.
7. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J & Fantini J. Mutation profiles of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. Journal of Clinical Microbiology 1999; 37:4099-4106.
8. Yahi N, Tamalet C, Tourres C, Tivoli N & Fantini J. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. Journal of Biomedical Science 2000; 7:507-513.
9. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD & D'Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. The Journal of Infectious Diseases 2000; 181:904-911.
10. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C & Calvez V. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Journal of Medical Virology 2004; 72:162-165.
11. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ & Shafer RW. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
12. Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J & Brun-Vezinet F. A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients. The Journal of Infectious Diseases 2004; 189:862-870.
13. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, Lengauer T, Selbig J, Vandamme AM, Korn K & Schmidt B. Tenofovir resistance and resensitization. Antimicrobial Agents and Chemotherapy 2003; 47:3478-3484.
14. Flandre P, Parkin NT, Petropoulos C & Chappey C. Competing occurrence and mutation profiles of nucleoside reverse transcriptase inhibitor associated mutations. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11 2004, San Francisco, USA. Abstract 645.
15. Delaugerre C, Mouroux M, Yvon-Groussin A, Simon A, Angleraud F, Huraux JM, Agut H, Katlama C & Calvez V. Prevalence and conditions of selection of E44D/A and V1181 human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice. Antimicrobial Agents and Chemotherapy 2001; 45:946-948.
16. Girouard M, Diallo K, Marchand B, McCormick S & Gotte M. Mutations E44D and V1181 in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. The Journal of Biological Chemistry 2003; 278:34403-34410.
17. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi R & Mellors J. K65R: A multinucleoside resistance mutation of increasing prevalence exhibits bidirectional phenotypic antagonism with TAM. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 54.
18. Kuritzkes DR, Shugarts D, Bakhtiari M, Poticha D, Johnson J, Rubin M, Gingeras TR, Kennedy M & Eron JJ. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 23:26-34.
19. Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J, Aboulker JP & Brun-Vezinet F. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antiviral Therapy 2003; 8:65-72.
20. Rhee SY, Liu T, Ravela J, Gonzales MJ & Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrobial Agents and Chemotherapy 2004; 48:3122-3126.
21. Masquelier B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferre V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vezinet F, Costagliola D; ANRS AC11 Resistance study group. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antiviral Therapy 2004; 9:315-323.
22. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A & Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. The Journal of Infectious Diseases 2004; 189:837-846.
23. Miranda LR, Gotte M, Kuritzkes DR. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrobial Agents and Chemotherapy 2005; 49:2648-2656.
24. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS & Kuritzkes DR. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. The Journal of Infectious Diseases 1995; 171:1172-1179.